[State Food and Drug Administration: Zhen Shiming and other 37 batches of drugs are unqualified] September 7th, reporters learned today that the latest drug sampling notice issued by the State Food and Drug Administration showed that 37 batches of drugs produced by 13 companies did not meet the regulations after inspection by five drug inspection agencies including the Beijing Institute of Drug Inspection and the Xiamen Institute of Food and Drug Quality Inspection. These include: The Xiamen Food and Drug Quality Inspection Institute found that the pH value of 4 batches of fluticasone propionate cream produced by Wuhan Nuoan Pharmaceutical Co., Ltd. did not meet the regulatory requirements. An inspection by the Beijing Institute of Drug Control found that a total of 23 batches of tobramycin and dexamethasone eye drops labeled as produced by Zhenshuiming (Jiangxi) Pharmaceutical Co., Ltd. and Chengdu Qingshan Likang Pharmaceutical Co., Ltd. did not meet regulatory requirements in terms of properties, particle size, and sterility. An inspection by the Fujian Provincial Food and Drug Quality Inspection Institute found that the relevant substances, iodide and content determination items of a batch of amiodarone hydrochloride injection labeled as produced by Shandong Beida Hi-Tech Huatai Pharmaceutical Co., Ltd. did not meet the regulatory requirements. An inspection by the Zhejiang Food and Drug Inspection Institute found that the impurities and content of 3 batches of coltsfoot flowers labeled as produced by Anhui Hansheng Pharmaceutical Co., Ltd., Chengdu Qilong Traditional Chinese Medicine Pieces Co., Ltd., and Sichuan Haobo Pharmaceutical Co., Ltd. did not meet the regulatory requirements. An inspection by the Shanghai Institute for Drug Control found that the properties, aflatoxin and content determination of a total of 6 batches of polygala produced by Anguo Xinlong Pharmaceutical Co., Ltd., Hebei Renxin Pharmaceutical Co., Ltd., Harbin Yifang Pharmaceutical Co., Ltd., Anhui Guiwan Pharmaceutical Co., Ltd., Shandong Fangfang Pharmaceutical Co., Ltd., and Sichuan Jinke Pharmaceutical Co., Ltd. did not meet the regulatory requirements. The State Food and Drug Administration stated that for these 37 batches of drugs, the drug regulatory department has required relevant companies and units to take risk control measures such as suspending sales and use, recalling, etc., to investigate the reasons for non-compliance with regulations, and to make practical rectifications. The State Food and Drug Administration requires relevant provincial drug regulatory authorities to investigate suspected illegal activities of the above-mentioned enterprises and units in accordance with China's "Drug Administration Law" and make the investigation results public in accordance with regulations.